Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 7kWORD 21k
18 May 2018
Answer given by Mr Moedas on behalf of the Commission
Question reference: E-001930/2018

1. The Commission is aware of the research referred to by the Honourable Member(1). The Commission does not hold data specifically on the effectiveness of the combination of a CpG(2) oligodeoxynucleotide and an antibody against OX40(3). However, research on similar T-cell checkpoint inhibitors is being supported through Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020)(4), for instance in the ‘Immunostimulatory Agonist antibodies for Cancer Therapy’ (IACT) and ‘Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy’ (BITCAT) projects(5), which are examining the potential of this approach for treating cancer.

2. The Horizon 2020 2018-2020 Work Programme offers opportunities to conduct research on potential benefits and risks of immunostimulating agents(6)-(7). Full information on funding opportunities under Horizon 2020 is available on the Research and Innovation Participant Portal(8)-(9) and on the ‘Access to EU Finance’ Europa website(10).

(2)Short DNA molecule containing cytosine triphosphate deoxynucleotide followed by a guanine triphosphate deoxynucleotide.
(3)A molecule that can be found on the surface of certain white blood cells of the immune system.
(5)IACT: https://cordis.europa.eu/project/rcn/110142_en.html BITCAT: https://cordis.europa.eu/project/rcn/206132_en.html
(6)Through the ‘Health, demographic change and wellbeing’ societal challenge, as well as the ‘Excellent science’ and ‘Industrial leadership’ pillars. http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing
(7)Research and Innovation Participant Portal: http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html

Last updated: 18 May 2018Legal notice